Black Diamond to Present Phase 2 Data of Silevertinib in Non-Small Cell Lung Cancer

Black Diamond Therapeutics will present Phase 2 data on silevertinib in non-small cell lung cancer today, including objective response rate and preliminary duration of treatment data from 43 patients. The drug is a brain-penetrant EGFR inhibitor being evaluated in three settings: first-line NSCLC with non-classical EGFR mutations, second/third-line NSCLC in C797S+ patients, and glioblastoma with EGFR. The company has $135.5 million in cash, which it expects to fund operations into Q4 2027.